BerandaAXGN • NASDAQ
add
AxoGen, Inc Common Stock
$10,50
Setelah Jam Perdagangan Normal:(0,00%)0,00
$10,50
Tutup: 27 Jun, 16.18.46 GMT-4 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$10,47
Rentang hari
$10,20 - $10,62
Rentang tahun
$7,09 - $21,00
Kapitalisasi pasar
478,21Â jt USD
Volume Rata-Rata
584,94Â rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
(USD) | Mar 2025info | Perubahan Y/Y |
---|---|---|
Pendapatan | 48,56Â jt | 17,36% |
Biaya operasional | 36,59Â jt | -1,58% |
Laba bersih | -3,83Â jt | 42,22% |
Margin laba bersih | -7,90 | 50,75% |
Penghasilan per saham | -0,02 | 66,67% |
EBITDA | 134,00Â rb | 104,50% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
(USD) | Mar 2025info | Perubahan Y/Y |
---|---|---|
Investasi tunai jangka pdk | 22,07Â jt | 25,15% |
Total aset | 196,16Â jt | 5,17% |
Total liabilitas | 90,80Â jt | -2,74% |
Total ekuitas | 105,36 jt | — |
Saham yang beredar | 45,54 jt | — |
Harga terhadap nilai buku | 4,51 | — |
Tingkat pengembalian aset | -2,08% | — |
Tingkat pengembalian modal | -2,36% | — |
Arus Kas
Perubahan kas bersih
(USD) | Mar 2025info | Perubahan Y/Y |
---|---|---|
Laba bersih | -3,83Â jt | 42,22% |
Kas dari operasi | -13,18Â jt | -7,44% |
Kas dari investasi | 1,34Â jt | 141,19% |
Kas dari pembiayaan | 2,38Â jt | 1.067,65% |
Perubahan kas bersih | -9,46Â jt | 38,24% |
Arus kas bebas | -12,34Â jt | -9,71% |
Tentang
Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available allograft approved by the Food and Drug Administration for clinical use. Wikipedia
Didirikan
2002
Kantor pusat
Situs
Karyawan
452